Probiotics and prebiotics in atopic dermatitis: Pros and cons (Review).

Content Provider	Europe PMC
Author	Fanfaret, Ionut Serban Boda, Daniel Ion, Laura Mihaela Hosseyni, Daniela Leru, Poliana Ali, Selda Corcea, Sabina Bumbacea, Roxana
Copyright Year	2020
Abstract	Atopic dermatitis (AD) represents a chronic inflammatory skin condition in which the skin barrier is impaired; thus, the permeability is increased. Hence, there is a greater risk of allergic sensitization, as well as a higher pH and lower protection against resident microbes. Since this condition is currently increasing among children, it requires further study, as little is known regarding the pathogenesis that makes the skin prone to chronic relapsing inflammation. Trying to standardize the data regarding the use of prebiotics and probiotics in AD, we encountered tremendous variability in the literature data. Literature abounds in conflicting data: studies regarding prophylactic and therapeutic applications, different types of strains and dosages, applications in young children up to 5 years of age and above, usage of probiotics alone, prebiotics alone or synbiotics combined. There are also conflicting data regarding the outcome of these studies; some confirming a positive effect of prebiotics, probiotics or synbiotics and some showing no efficacy at all. The articles were divided into those assessing probiotics or prebiotics alone and a combination of the two, with studies showing a positive effect and studies proving no efficacy at all. We tried to critically analyze those articles showing weak and strong points. In summary, the most studied probiotics were the strains of Lactobacilli and Bifidobacteria. The Severity Scoring of Atopic Dermatitis (SCORAD) index was used to measure the efficacy of the treatment. Most studies compared their results with a placebo group and the efficacy when seen in moderate to severe forms of AD in patients with other allergic diseases present. However, the results are difficult to interpret, as in many studies the authors suggest that the disease may have a tendency to improve in time in some groups of patients.
ISSN	17920981
Journal	Experimental and Therapeutic Medicine
Volume Number	22
PubMed Central reference number	PMC8506923
Issue Number	6
PubMed reference number	34650624
e-ISSN	17921015
DOI	10.3892/etm.2021.10811
Language	English
Publisher	D.A. Spandidos
Publisher Date	2021-09-28
Access Restriction	Open
Rights License	This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. Copyright: © Fanfaret et al.
Subject Keyword	atopic dermatitis prebiotics probiotics synbiotics gut microbiome chronic ski inflammation
Content Type	Text
Resource Type	Article
Subject	Immunology and Microbiology Cancer Research